Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
AstraZeneca (NYSE: AZN) recently impressed a crowd of oncologists at the annual San Antonio Breast Cancer Symposium with surprisingly good clinical trial results. In a nutshell, it looks like an experimental drug that the company licensed from Daiichi Sankyo (OTC: DSNKY) c...
Daiichi Sankyo ( OTCPK:DSNKY ) and commercialization partner AstraZeneca (NYSE: AZN ) announce that the FDA has accepted for review the marketing application for antibody-drug conjugate (ADC) [fam-] trastuzumab deruxtecan (DS-8201) for HER2-positive metastatic breast cancer. Under Pri...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this Read more ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...
- Global and European real-world outcome analyses in non-selected atrial fibrillation (AF) patients on edoxaban, including those who are elderly with comorbidities, were reported at ESC Congress 2019 - At present, the Global ETNA-AF programme is the largest and most comprehens...
Back in May, Esperion Therapeutics ( ESPR ) announced the FDA set two PDUFA dates in February for the company's two leading products, bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are looking to be approved to treat elevated low-density lipo...
The FDA approves Daiichi Sankyo's ( OTCPK:DSNKY +0.2% ) Turalio (pexidartinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations that cannot be improved with surgery. More news on: Daiich...
Daiichi Sankyo Company ( OTCPK:DSNKY ): Q1 GAAP EPS of ¥66.77. Revenue of ¥249.24B (+10.4% Y/Y) Press Release More news on: Daiichi Sankyo Company, Limited, Daiichi Sankyo Company, Limited, Earnings news and commentary,
Preliminary data from a Phase 1 dose-escalation study evaluating Daiichi Sankyo's ( OTCPK:DSNKY ) HER3-targeting antibody-drug conjugate (ADC) U3-1402 in 23 patients with metastatic EGFR mutation-positive, TKI-resistant non-small cell lung cancer (NSCLC) showed encouraging action. The re...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...